Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast CancerGuillermo Villacampa, Tomás Pascual, Vı́ctor Navarro et al.|JAMA Oncology|2024Cited by 77
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Theodoros Foukakis, Jonas Bergh et al.|Clinical Cancer Research|2022Cited by 41
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter StudyUna Kjällquist, Johan Hartman, Balázs Ács et al.|Cancers|2022Cited by 21
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, I. Thalmann, Volker Möbus et al.|Journal of Clinical Oncology|2024Cited by 11
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Jonas Bergh, Sara Margolin et al.|Breast Cancer Research and Treatment|2017Cited by 8